BACKGROUND: Dendritic cell (DC)-based and cytokine-induced killer cell (CIK)-based therapy can induce specific antitumor T-cell responses. This clinical pilot study examined the safety, the feasibility, and the outcome of tumor-specific immunotherapy for patients with advanced pancreatic adenocarcinoma. METHODS: Alpha-Gal epitopes were synthesised on pancreatic carcinoma cell membranes with α1,3-galactosyltransferase in vitro. Subsequently, the addition of natural human anti-Gal IgG to the processed membranes resulted in opsonization and effective phagocytosis by DCs, which were co-cultured with newly differentiated CIKs from bone marrow stem cells to generate tumor-specific immune responders ex vivo. Fourteen patients with inoperable stage III/IV pancreatic adenocarcinoma were enrolled in the study; the treatment procedure consisted of injections of DCs and CIKs. RESULTS: Clinical observation showed that the procedure was safe and lacked serious side effects. Tests showed that 12 patients had strong positive delayed-type IV hypersensitivity to the autologous cancer cell lysate; robust systemic cytotoxicity elicited by interferon (IFN)γ expression by peripheral blood mononuclear cells; and significant increases in CD3+CD8+, CD3+CD45RO+, and CD3+CD56+ cells in peripheral blood lymphocytes after 3 injections. During the follow up, the percentages of CD3+CD8+, CD3+CD45RO+, and CD3+CD56+ cells returned to the normal range at 6 to 9 months after the third injection and IFNγ expression in the cells stayed at the higher level from the third injection to 24 months after the treatment. CONCLUSIONS: This new tumor-specific immunotherapy is safe, feasible, and has great potential for pancreatic carcinoma treatment.
BACKGROUND: Dendritic cell (DC)-based and cytokine-induced killer cell (CIK)-based therapy can induce specific antitumor T-cell responses. This clinical pilot study examined the safety, the feasibility, and the outcome of tumor-specific immunotherapy for patients with advanced pancreatic adenocarcinoma. METHODS: Alpha-Gal epitopes were synthesised on pancreatic carcinoma cell membranes with α1,3-galactosyltransferase in vitro. Subsequently, the addition of natural human anti-Gal IgG to the processed membranes resulted in opsonization and effective phagocytosis by DCs, which were co-cultured with newly differentiated CIKs from bone marrow stem cells to generate tumor-specific immune responders ex vivo. Fourteen patients with inoperable stage III/IV pancreatic adenocarcinoma were enrolled in the study; the treatment procedure consisted of injections of DCs and CIKs. RESULTS: Clinical observation showed that the procedure was safe and lacked serious side effects. Tests showed that 12 patients had strong positive delayed-type IV hypersensitivity to the autologous cancer cell lysate; robust systemic cytotoxicity elicited by interferon (IFN)γ expression by peripheral blood mononuclear cells; and significant increases in CD3+CD8+, CD3+CD45RO+, and CD3+CD56+ cells in peripheral blood lymphocytes after 3 injections. During the follow up, the percentages of CD3+CD8+, CD3+CD45RO+, and CD3+CD56+ cells returned to the normal range at 6 to 9 months after the third injection and IFNγ expression in the cells stayed at the higher level from the third injection to 24 months after the treatment. CONCLUSIONS: This new tumor-specific immunotherapy is safe, feasible, and has great potential for pancreatic carcinoma treatment.
Authors: L Adamson; A Palmborg; A Svensson; A Lundqvist; M Hansson; R Kiessling; G Masucci; H Mellstedt; P Pisa Journal: Cytotherapy Date: 2004 Impact factor: 5.414
Authors: Sunil Krishnan; Vishal Rana; Nora A Janjan; James L Abbruzzese; Morris S Gould; Prajnan Das; Marc E Delclos; Shana Palla; Sushovan Guha; Gauri Varadhachary; Douglas B Evans; Robert A Wolff; Christopher H Crane Journal: Cancer Date: 2006-12-01 Impact factor: 6.860
Authors: Kenneth W Hance; Connie J Rogers; David A Zaharoff; Daniel Canter; Jeffrey Schlom; John W Greiner Journal: Clin Cancer Res Date: 2009-03-10 Impact factor: 12.531
Authors: Mark R Albertini; Erik A Ranheim; Cindy L Zuleger; Paul M Sondel; Jacquelyn A Hank; Alan Bridges; Michael A Newton; Thomas McFarland; Jennifer Collins; Erin Clements; Mary Beth Henry; Heather B Neuman; Sharon Weber; Giles Whalen; Uri Galili Journal: Cancer Immunol Immunother Date: 2016-05-20 Impact factor: 6.968